Special Topics in the Care of Older People with HIV
- 4 Downloads
Purpose of review
Antiretroviral therapy has enabled many people with HIV to live long lives with their infection, but the literature suggests that long-term survivors are developing comorbidities and aging-related syndromes at earlier ages than their non-infected counterparts. In addition, there is evidence of sex-based differences in comorbidity risk.
How to best care for people aging with HIV is not known, but the tools of comprehensive geriatric assessment can identify people at risk for decline. Newer antiretroviral therapies offer promise of fewer side effects and drug interactions. We will also discuss special needs of women aging with HIV.
People with HIV and their providers are often unprepared to confront issues of aging, and each clinical program must develop methods to assess older patients and manage age-related complications and syndromes.
KeywordsAging Geriatric syndromes Women’s health Comprehensive geriatric assessment Stigma HIV
Compliance with Ethical Standards
Conflict of Interest
Dr. Siegler has received salary support for an investigator-initiated study from Gilead Sciences, Inc.
Drs. Johnston and Del Carmen and Ms. Burchett declare that they have no conflicts of interest.
Dr. Johnston has grant support from NIH/NIAID T32 AI007613.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Centers for Disease Control and Prevention. HIV Surveillance Report 2017 [Internet]. 2018 [cited 2019 Feb 13] p. 129. Report No.: Volume 29. Available from: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
- 3.HIV Epidemiology and Field Services Program. 2017 HIV Surveillance Annual Report [Internet]. New York, NY: New York City Department of Health and Mental Hygiene; 2018. [cited 2019 Feb 13] p. 20. Available from: https://www1.nyc.gov/assets/doh/downloads/pdf/dires/hiv-surveillance-annualreport-2017.pdf.Google Scholar
- 5.Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional Comparison of the Prevalence of Age-Associated Comorbidities and Their Risk Factors Between HIV-Infected and Uninfected Individuals: The AGEhIV Cohort Study. Clin Infect Dis. 2014;59(12):1787–97.PubMedCrossRefGoogle Scholar
- 6.Kong AM, Pozen A, Anastos K, Kelvin EA, Nash D. Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis. AIDS Patient Care STDs. 2019;33(3):93–103.PubMedCrossRefGoogle Scholar
- 7.Guaraldi G, Malagoli A, Calcagno A, Mussi C, Celesia BM, Carli F, et al. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 – 74 years and more than 75 years. BMC Geriatr. 2018;18(1):99.PubMedPubMedCentralCrossRefGoogle Scholar
- 10.Do AN, Rosenberg ES, Sullivan PS, Beer L, Strine TW, Schulden JD, et al. Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveillance system. PLoS One. 2014;9(3):e928423.Google Scholar
- 11.Kelly SG, Wu K, Tassiopoulos K, Erlandson KM, Koletar SL, Palella FJ. Frailty Is an Independent Risk Factor for Mortality, Cardiovascular Disease, Bone Disease, and Diabetes Among Aging Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2019; 27;69(8):1370–1376. Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciy1101/5258114. Accessed 29 Dec 2019CrossRefGoogle Scholar
- 12.The White House Office of National AIDS Policy. National HIV/AIDS Strategy for The United States: Updated to 2020. 2015;74. https://files.hiv.gov/s3fs-public/nhas-update.pdf. Accessed 11 May 2019
- 15.Shen MJ, Freeman R, Karpiak S, Brennan-Ing M, Seidel L, Siegler EL. The intersectionality of stigmas among key populations of older adults affected by HIV: a thematic analysis. Clin Gerontol. 2018;0(ja):1–13.Google Scholar
- 17.Turan B, Smith W, Cohen MH, Wilson TE, Adimora AA, Merenstein D, et al. Mechanisms for the Negative Effects of Internalized HIV-Related Stigma on Antiretroviral Therapy Adherence in Women: The Mediating Roles of Social Isolation and Depression. J Acquir Immune Defic Syndr. 2016;72(2):198–205.PubMedPubMedCentralCrossRefGoogle Scholar
- 18.• Stangl AL, Earnshaw VA, Logie CH, van Brakel W, C. Simbayi L, Barré I, et al. The Health Stigma and Discrimination Framework: a global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas. BMC Med. 2019;17(1):31 Recognizing the importance of better addressing health related stigmas, the Health Stigma and Discrimination Framework was developed to enhance methods for research and policy.PubMedPubMedCentralCrossRefGoogle Scholar
- 21.Greene ML, Tan JY, Weiser SD, Christopoulos K, Shiels M, O’Hollaren A, et al. Patient and provider perceptions of a comprehensive care program for HIV-positive adults over 50 years of age: The formation of the Golden Compass HIV and aging care program in San Francisco. PLoS One. 2018;13(12):e0208486.PubMedPubMedCentralCrossRefGoogle Scholar
- 22.Siegler EL. Care of People Aging with HIV: Northeast/Caribbean AETC Toolkit, V.4 [Internet]: Northeast Caribbean AIDS Education and Training Center Program; 2018. Available from: https://necaaetc.org/file/949/download?token=qf8-RrNg.
- 23.NECA AETC Clinical Support Tools [Internet]. 2019 [cited 2019 Mar 3]. Available from: https://necaaetc.org/content/clinical-support-tools.
- 26.•• Montoya JL, Jankowski CM, O’Brien KK, Webel AR, Oursler KK, Henry BL, et al. Evidence-informed practical recommendations for increasing physical activity among persons living with HIV. AIDS. 2019;33(6):931–9 This review reinforces the central role increasing physical activity plays in the health of people with HIV.PubMedCrossRefGoogle Scholar
- 27.Hakkers CS, Kraaijenhof JM, van Oers-Hazelzet EB, Visser-Meily AJMA, Hoepelman AIM, Arends JE, et al. HIV and Cognitive Impairment in Clinical Practice: The Evaluation of a Stepwise Screening Protocol in Relation to Clinical Outcomes and Management. AIDS Patient Care STDs. 2017;31(9):363–9.PubMedCrossRefGoogle Scholar
- 35.• Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. US Department of Health and Human Services; 2013. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/aa_recommendations.pdf. The DHHS Guidelines includes a section about HIV in Older Adults under the category of “HIV in Specific Populations”.
- 36.Food and Drug Administration. FDA Approves the First Once-a-Day Three-Drug Combination Tablet for Treatment of HIV-1 News [Internet]. AIDSinfo. [cited 2019 May 8]. Available from: https://aidsinfo.nih.gov/news/769/fda-approves-the-first-once-a-day-three-drug-combination-tablet-for-treatment-of-hiv-1.
- 37.• Llibre JM, Hung C-C, Brinson C, Castelli F, Girard P-M, Kahl LP, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839–849. This study demonstrates non-inferiority of a novel two drug regimen to maintain viral suppression in individuals with suppressed viremia on a stable ARV regimen.CrossRefGoogle Scholar
- 38.Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143–55.PubMedCrossRefPubMedCentralGoogle Scholar
- 40.Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults - Full Text View - ClinicalTrials.gov [Internet]. Clinical Trials.gov. [cited 2019 Mar 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02951052.
- 41.Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants - Full Text View - ClinicalTrials.gov [Internet]. ClinicalTrials.gov. [cited 2019 May 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02938520.
- 42.Swindells S, Andrade-Villanueva J, Richmond G, Rizzardini G, Baumgarten A, Masia MDM, et al. Long-acting cabotegravir + rilpivirine as maintenance therapy: ATLAS week 48 results | CROI Conference [Internet]. [cited 2019 May 8]. Available from: http://www.croiconference.org/sessions/long-acting-cabotegravir-rilpivirine-maintenance-therapy-atlas-week-48-results.
- 43.Orkin C, Arastéh K, Hernández-Mora MG, Pokrovsky V, Overton ET, Girard P-M, et al. Long-acting cabotegravir + rilpivirine for HIV maintenance: FLAIR week 48 results | CROI Conference [Internet]. [cited 2019 May 8]. Available from: http://www.croiconference.org/sessions/long-acting-cabotegravir-rilpivirine-hiv-maintenance-flair-week-48-results.
- 53.Andany N, Kennedy VL, Aden M, Loutfy M. Perspectives on menopause and women with HIV [Internet]. International Journal of Women’s Health. 2016; 11;8:1-22 Available from: https://www.dovepress.com/perspectives-on-menopause-and-women-with-hiv-peer-reviewed-fulltext-article-IJWH. Accessed 9 May 2019
- 54.Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):1–10.PubMedCrossRefGoogle Scholar
- 57.Womack JA, Chang C-CH, So-Armah KA, Charles A, Baker Jason V, Brown Sheldon T, et al. HIV Infection and Cardiovascular Disease in Women. J Am Heart Assoc. 3(5):e001035.Google Scholar
- 59.Bairey Merz CN, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M, et al. Insights From the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part II: Gender Differences in Presentation, Diagnosis, and Outcome With Regard to Gender-Based Pathophysiology of Atherosclerosis and Macrovascular and Microvascular Coronary Disease. J Am Coll Cardiol. 2006;47(3, Supplement):S21–9.PubMedCrossRefGoogle Scholar
- 61.•• Maki PM, Rubin LH, Springer G, Seaberg EC, Sacktor N, Miller EN, et al. Differences in Cognitive Function Between Women and Men With HIV. JAIDS J Acquir Immune Defic Syndr.. 2018;79(1):101 This provocative study provides evidence that women with HIV are more vulnerable to HIV related cognitive dysfunction than their male counterparts.PubMedCrossRefGoogle Scholar
- 64.• Chow FC, Regan S, Zanni MV, Looby SE, Bushnell CD, Meigs JB, et al. Elevated ischemic stroke risk among women living with HIV infection. AIDS. 2018;32(1):59 This study identified where HIV modifies the impact of sex specific risk factors on stroke risk in women with HIV.PubMedPubMedCentralCrossRefGoogle Scholar
- 70.Kanis JA on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. [Internet]. UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield; 2007. [cited 2019 May 11]. Available from: www.who.int/chp/topics/rheumatic/en/index.html Google Scholar